Q-omics provides the consensus-scored CENPU profile across patient tissues and cancer cell-line models. CENPU expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CENPU is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, CENPU RNA expression shows 18,483 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where CENPU shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CENPU — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CENPU survival associations across molecular data types. CENPU RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CENPU RNA expression–survival associations across cancer types. High CENPU expression shows unfavorable associations in ACC, KIRP, MESO, LUAD, LIHC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CENPU RNA expression.
This table summarizes CENPU tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CENPU. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CENPU shows higher tumor expression in BLCA, KIRC, KIRP, LUAD, THCA and LUSC. The BLCA box plot shows higher CENPU RNA expression in tumor versus normal tissue (log2 FC = +2.701, t-test p < 0.001).
This table shows molecular features associated with CENPU in patient tissues and cancer cell lines. In patient samples, CENPU shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CENPU RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OESOPHAGUS.
